Evolus, Inc. EOLS
We are a global performance beauty company delivering breakthrough products with a customer-centric approach. Our primary market is the cash-pay aesthetic market, which consists of medical products that consumers pay for directly out of pocket. Our customers are aesthetic practitioners who are properly licensed to deliver our products. By avoiding the regulatory burdens that accompany reimbursed products and pursuing an aesthetic-only non-reimbursed product strategy, we believe that we create flexibility to deliver a unique value proposition to our customers. We utilize this flexibility to drive customer adoption efforts through programs such as our consumer loyalty program, co-branded marketing programs, promotional events and pricing strategies.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $297.2M | $266.3M | $202.1M | $148.6M | $99.7M | $56.5M | $34.9M | $0 | — | — |
| Cost of revenue | $100.1M | $84.0M | $64.5M | $58.8M | $43.5M | $18.3M | $8.0M | $0 | — | — |
| Gross profit | $197.1M | $182.3M | $137.6M | $89.8M | $56.1M | $38.2M | $26.9M | $0 | — | — |
| R&D | — | — | — | — | $2.1M | $1.7M | $4.0M | $6.5M | $6.7M | — |
| SG&A | $220.8M | $198.0M | $164.9M | $141.8M | $112.1M | $98.2M | $113.6M | $29.1M | $4.8M | — |
| Total operating expenses | $229.8M | $216.7M | $186.8M | $155.1M | $144.1M | $209.6M | $133.9M | $46.1M | $11.7M | — |
| Operating income | -$32.7M | -$34.4M | -$49.2M | -$65.3M | -$44.4M | -$153.1M | -$98.9M | -$46.1M | -$11.7M | — |
| Interest expense | $19.7M | $18.7M | $13.8M | $9.1M | $1.4M | — | — | $863.0K | $5.0K | — |
| Pre-tax income | -$51.0M | -$49.8M | -$61.5M | -$74.3M | -$46.8M | -$162.9M | -$105.1M | -$46.8M | -$11.7M | — |
| Income tax | $677.0K | $664.0K | $176.0K | $95.0K | $42.0K | $77.0K | $15.0M | $65.0K | $7.3M | — |
| Net income | -$51.6M | -$50.4M | -$61.7M | -$74.4M | -$46.8M | -$163.0M | -$90.0M | -$46.9M | -$4.5M | — |
| EPS, basic | -0.80 | -0.81 | -1.08 | -1.33 | -0.94 | -4.83 | — | — | — | — |
| EPS, diluted | -0.80 | -0.81 | -1.08 | -1.33 | -0.94 | -4.83 | -3.19 | -1.92 | -0.27 | — |
| Shares, diluted (wtd. avg.) | 64.5M | 62.0M | 56.9M | 56.1M | 49.8M | 33.7M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $53.8M | $87.0M | $62.8M | $53.9M | $146.3M | $102.6M | $109.9M | $93.2M | $0 | $187.0K |
| Short-term investments | — | — | — | — | $0 | $5.0M | $19.9M | $0 | — | — |
| Receivables | $54.7M | $47.7M | $30.5M | $22.4M | $14.7M | $9.7M | $10.7M | $0 | — | — |
| Inventory | $27.0M | $12.2M | $11.0M | $18.9M | $1.8M | $3.4M | $6.4M | $0 | — | — |
| Total current assets | $142.9M | $151.3M | $112.4M | $100.8M | $178.8M | $127.6M | $152.2M | $94.3M | $72.8M | — |
| Property, plant and equipment | $5.4M | $3.2M | $2.1M | $2.6M | $1.4M | $1.3M | $902.0K | $0 | — | — |
| Goodwill | $21.2M | $21.2M | $21.2M | $21.2M | $21.2M | $21.2M | $21.2M | $21.2M | $21.2M | — |
| Other intangibles | $48.0M | $48.8M | $47.1M | $48.6M | $50.6M | $55.3M | $59.6M | $56.1M | $56.1M | — |
| Total assets | $225.9M | $232.6M | $189.0M | $178.0M | $257.5M | $209.1M | $240.4M | $171.8M | $152.2M | — |
| Accounts payable | $23.4M | $9.2M | $4.3M | $8.9M | $6.1M | $9.6M | $5.8M | $1.6M | $445.0K | — |
| Total current liabilities | $75.3M | $63.0M | $48.3M | $46.5M | $57.7M | $180.2M | $24.4M | $5.3M | $212.7M | — |
| Long-term debt | $146.1M | $121.5M | $120.4M | $71.9M | $71.2M | — | $73.5M | $0 | — | — |
| Total liabilities | $249.0M | $227.0M | $209.7M | $159.5M | $175.6M | $282.0M | $161.0M | $87.5M | $227.8M | — |
| Retained earnings | -$661.0M | -$609.4M | -$559.0M | -$497.3M | -$422.9M | -$376.1M | -$213.1M | -$123.0M | -$75.5M | — |
| Total equity | -$23.1M | $5.5M | -$20.7M | $18.5M | $81.9M | -$73.0M | $79.5M | $84.4M | -$75.5M | -$7.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$42.3M | -$18.0M | -$34.0M | -$84.9M | -$33.4M | -$57.9M | -$93.4M | -$25.7M | -$13.2M | — |
| Depreciation and amortisation | $7.5M | $5.3M | $5.1M | $3.7M | $5.6M | $7.0M | $4.1M | $9.0K | $218.0K | — |
| Stock-based compensation | $20.7M | $22.3M | $16.5M | $10.8M | $9.6M | $10.6M | $9.5M | $7.0M | $586.0K | — |
| Capital expenditure | $3.4M | $1.5M | $473.0K | $1.6M | $393.0K | $815.0K | $345.0K | $9.0K | $0 | — |
| Investing cash flow | -$8.5M | -$4.8M | -$1.6M | -$2.9M | $4.0M | $12.2M | -$23.4M | -$9.0K | $0 | — |
| Financing cash flow | $17.3M | $47.4M | $44.6M | -$4.1M | $73.1M | $38.3M | $133.5M | $118.8M | $13.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001570562-26-000059.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $34.9M | $56.5M | $99.7M | $148.6M | $202.1M | $266.3M | $297.2M |
| Gross profit | — | — | $0 | $26.9M | $38.2M | $56.1M | $89.8M | $137.6M | $182.3M | $197.1M |
| Net income | — | -$4.5M | -$46.9M | -$90.0M | -$163.0M | -$46.8M | -$74.4M | -$61.7M | -$50.4M | -$51.6M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed Item 1.01
- Regulation FD disclosure Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Material agreement signed Item 1.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |